Patent Analysis
Patent Analysis
Sale
The cancer immunotherapy market was valued at USD 118.97 billion in 2023. It is expected to grow at a CAGR of 11.6% during the forecast period of 2024-2032 and attain a market value of USD 319.45 billion by 2032.
The market is expected to grow due to the increasing adoption of targeted therapy, and the emergence of biosimilars for oncology treatment. The promising future of immunotherapy as a treatment option for cancer has boosted the intellectual property landscape. Many companies and research institutions have filed patent applications for multiple drugs and targets to protect their inventions in the immunotherapy field.
The immunotherapy in oncology patent landscape report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for immunotherapy in oncology include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within immunotherapy in oncology technologies.
As of May 2017, 1300+ patent families existed that recited both CTL A-4 and antibody in their claims. Moreover, approximately 500 patent families are directed to antibodies against the PD-1/PD-L1 interaction, 100 patent families are directed to antibodies and TIM3 or LAG 3, while around 300 patent families are directed to antibodies and OX40. The patent claim language is crucial for the protection of inventions, and thus the patent filings are witnessing a surge, impacting the landscape significantly.
Immunotherapy is a specialized treatment in which a person’s own immune system is used to fight cancer cells. This treatment can boost how the immune system attacks the cancer cells. This can be done in several ways, including stimulating the natural defenses of the immune system to attack cancer cells or by making substances in a lab, like immune system components and using that to restore the working of the immune system to attack cancer cells. There are multiple types of immunotherapies including checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, immunomodulators, cancer vaccines, and monoclonal antibodies.
The first commercial development of therapeutic monoclonal antibodies began in the 1980s. Since then, monoclonal antibodies have emerged as one of the major drug classes in the field of biopharmaceuticals.
Successful Clinical Trials for Immune Checkpoint Inhibitors and CAR T-Cell Therapies is Expected to Augment the Patent Industry Growth
The successful development in the immunotherapy treatments, such as immune checkpoint inhibitors and CAR-T cell therapies has fueled the investment in this field. The positive clinical trial results reflecting improved and efficient treatment outcomes are driving the demand for protection of patents to secure market exclusivity.
The noticeable advancement in cancer immunotherapy is the FDA approval of checkpoint inhibitors including PD-1/PD-L1 inhibitors such as Nivolumab, Pembrolizumab, Avelumab, and Atezolizumab. These therapies have significantly improved the treatment outcomes of renal cancer, bladder cancer, on-small cell lung cancer (NSCLC), head and neck cancer and melanoma. Therefore, it is essential to develop strong patent portfolios to protect such innovative therapies.
Shifting Trend towards Combination Therapies is Expected to Propel Immunotherapy in Oncology Patent Industry Growth
There is an ongoing trend towards combining more than one immunotherapy with other treatment options including such as chemotherapy or radiation therapy. This combined approach is driving innovation and an increase in patent filings.
The monoclonal antibodies along with other antibody-related products including antibody fragments, and antibody-drug conjugates, have emerged as a major drug class. This combinatory treatment has proven effective for cancer treatment. Companies are filing patents to protect novel combination therapies, thereby impacting the patent landscape significantly.
The report will cover the following sections in detail:
Breakup by Type
Breakup by Indication
The breakup based on type, includes monoclonal antibodies, cytokines and immunomodulators, checkpoint inhibitors, and others.
For instance, T-cell therapy is a successful treatment in the biopharmaceutical industry. This therapy involves reprogramming a patient’s own immune T cells to attack tumors. A type of T-cell therapy comprises the adoptive transfer of chimeric antigen receptor (CAR) T-cells. The benefit of CAR T-cells include that such cells can be engineered to target any tumor-associated antigen.
The detailed technological data will be provided for all specified segments classified in this report.
The United States is one of the leading jurisdictions for oncology immunotherapy patents, having around 34,000 patents. The presence of major pharmaceutical companies, well-established healthcare infrastructure, and advanced research and development activities contributes to the patent landscape significantly.
Among the players in oncology immunotherapy patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:
Bristol Myers Squibb Co
Bristol Myers Squibb, founded in 1887 and headquartered in the United States is a global pharmaceutical company engaged in the development of multiple therapeutic areas including cancer, cardiovascular diseases, hepatitis, diabetes, and psychiatric disorders among others. The company developed Ipilimumab, a drug that targets CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) and continues to research and develop in the field of immunotherapy.
Novartis AG
Novartis AG, founded in 1996 and headquartered at Switzerland, is a global pharmaceutical company, engaged in development of therapies in multiple areas including oncology, respiratory diseases, neurological disorders, and diabetes among others. Novartis has filed numerous patents to protect its IPs within oncology immunotherapies.
Other companies include Genentech Inc., AstraZeneca, Immatics Biotechnologies Gmbh, F. Hoffmann La Roche, Incyte Corp, and others.
The immunotherapy in oncology patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -
Scope of the Report | Details |
Analysis by Type |
|
Indication |
|
Key Players Mentioned |
|
Geographies Covered |
|
Global Cancer Immunotherapy Market
Global Immunotherapy Drugs Market
Global Monoclonal Antibodies Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Introduction
2 Executive Summary
3 Global Immunotherapy in Oncology Market Overview
3.1 Global Immunotherapy in Oncology Market Historical Value (2017-2023)
3.2 Global Immunotherapy in Oncology Market Forecast Value (2024-2032)
4 Global Immunotherapy in Oncology Market Segmentation
4.1 Global Immunotherapy in Oncology Market Share by Type
4.1.1 Market Overview
4.1.2 Monoclonal Antibodies
4.1.3 Cytokines &Immunomodulators
4.1.4 Checkpoint Inhibitors
4.1.5 Others
4.2 Global Immunotherapy in Oncology Market Share by Indication
4.2.1 Market Overview
4.2.2 Lung Cancer
4.2.3 Colorectal Cancer
4.2.4 Melanoma
4.2.5 Breast Cancer
4.2.6 Prostate Cancer
4.2.7 Others
5 Global Market Dynamics
5.1 Market Drivers and Constraints
5.2 Porter’s Five Forces Analysis
5.3 PESTEL Analysis
5.4 Industry Events, Initiatives, and Trends
5.5 Value Chain Analysis
6 Global Immunotherapy in Oncology Patent Landscape Analysis
6.1 Patent Distribution by Publication Year
6.2 Patent Distribution by Application Year
6.3 Patent Distribution by Priority Year
6.4 Analysis by Type of Patent
6.4.1 Granted Patents
6.4.2 Patent Application
6.4.3 Amended Application
6.4.4 Search Report
6.5 Analysis by Legal Status
6.5.1 Active
6.5.2 Pending
6.5.3 Expired/Discontinued
6.6 Analysis by Patent Jurisdiction
6.7 Analysis by Patent Age
6.8 Analysis by Cooperative Patent Classification (CPC) Codes
6.9 Average Time to Publish a Patent
6.9.1 By Entities
6.9.2 By Jurisdiction
6.9.3 By Technology
6.10 Analysis by Type of Entity (Academic and Non-Academic)
6.11 Analysis by Top Applicants
6.12 Analysis by Top Inventors
7 Global Immunotherapy in Oncology Patent Analysis by Technology
7.1 Total Patents by Top Technologies
7.2 Time Evolution of Patents by Technology
7.3 Emerging Technologies
7.4 Patent Segmentation, By Type
7.4.1 Time Evolution by Number of Patents
7.4.2 Time Evolution by Number of Patent Families
7.4.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.4.4 Analysis by Top Applicants
7.4.5 Analysis by Top Inventors
7.5 Patent Segmentation, By Indication
*Complete technology list will be provided in the report.
8 EMR Patent Valuation Analysis
8.1 Assessment Methodology
8.2 High Value Patents
8.3 Medium Value Patents
8.4 Low Value Patents
9 Global Immunotherapy in Oncology – Top 10 Players Patent Analysis
9.1 Top 10 Entities by Number of Patents
9.2 Analysis by Publication Year
9.3 Analysis by Application Year
9.4 Analysis by Priority Year
9.5 Analysis by Type of Patent
9.6 Analysis by Jurisdiction
9.7 Analysis by Cooperative Patent Classification (CPC) Codes
9.8 Analysis by Source of Innovation
9.9 Analysis by Forward and Backward Citations
9.10 Analysis by Legal Status
9.11 Analysis by Patent Age
9.12 Analysis by Key Inventors
9.13 Entity Dynamics
9.13.1 Analysis by Type of Player (Academic vs Non-Academic)
9.13.2 Analysis by Collaboration
9.13.3 Analysis by Technology
9.13.4 Newcomers
9.13.4.1 Start-up Companies
9.13.4.2 Established Companies
10 Patent Profile of Key Players
10.1 Genentech Inc .
10.1.1 Product Portfolio
10.1.2 Patent Portfolio by Patent Families
10.1.3 Time Evolution of Patents
10.1.4 Geographical Patent Coverage
10.1.5 Patent Analysis by Technology
10.1.6 Patent News and Developments
10.1.7 Financial Analysis
10.1.8 SWOT Analysis
10.2 Astrazeneca PLC
10.3 Bristol Myers Squibb Co
10.4 Novartis AG
10.5 Immatics Biotechnologies Gmbh
10.6 F. Hoffmann-La Roche AG
10.7 Incyte Corp
11 Future Trends
12 Global Immunotherapy in Oncology Market Landscape (Additional Insight)*
12.1 Global Immunotherapy in Oncology: Developers Landscape
12.1.1 Analysis by Year of Establishment
12.1.2 Analysis by Company Size
12.1.3 Analysis by Region
12.2 Global Immunotherapy in Oncology: Product Landscape
12.2.1 Analysis by Product Type
12.2.2 Analysis by Technology
12.2.3 Analysis by Application
*Additional insights are not provided in the standard report.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.